Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Natera Inc
(NQ:
NTRA
)
127.61
-4.32 (-3.27%)
Streaming Delayed Price
Updated: 3:26 PM EDT, Oct 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Natera Inc
< Previous
1
2
3
4
5
6
Next >
Natera to Report its Third Quarter 2023 Results on November 8
October 20, 2023
From
Natera, Inc.
Via
Business Wire
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
October 19, 2023
From
Natera, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
October 16, 2023
From
Natera, Inc.
Via
Business Wire
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
October 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
October 04, 2023
From
Natera, Inc.
Via
Business Wire
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
October 03, 2023
From
Natera, Inc.
Via
Business Wire
Natera Submits First PMA Module to the FDA for Signatera™
October 02, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Senior Leadership Appointments
September 18, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
September 14, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Pricing of $250 Million Follow-On Offering
September 07, 2023
From
Natera, Inc.
Via
Business Wire
Natera Launches Proposed Follow-On Offering
September 06, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Participate in Upcoming Investor Conferences
September 01, 2023
From
Natera, Inc.
Via
Business Wire
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
August 16, 2023
From
Natera, Inc.
Via
Business Wire
Natera Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Natera, Inc.
Via
Business Wire
Natera Files Patent Infringement Suit Against NeoGenomics
July 31, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
July 28, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Report its Second Quarter 2023 Results on August 3rd
July 27, 2023
From
Natera, Inc.
Via
Business Wire
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
July 17, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
June 04, 2023
From
Natera, Inc.
Via
Business Wire
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
May 30, 2023
From
Natera, Inc.
Via
Business Wire
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
May 15, 2023
From
Natera, Inc.
Via
Business Wire
Natera Reports First Quarter 2023 Financial Results
May 09, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
May 08, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces First Quarter 2023 Earnings Conference Call
May 02, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
April 14, 2023
From
Natera, Inc.
Via
Business Wire
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
March 22, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Commercial Payor Coverage for Signatera™
March 02, 2023
From
Natera, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.